The recommendation for approval of neratinib, according to 21 Code of Federal Regulations (CFR) 314.126(a)(b), is primarily based on the efficacy and safety data from a single trial (Study 3004, ExteNET), a multicenter, randomized, double-blind, placebo-controlled trial of one year of neratinib versus placebo in women with early stage HER2-positive breast cancer after adjuvant treatment with trastuzumab.